Neuland Laboratories Limited announced the approval of its Unaudited Financial Results for the quarter and nine months ended December 31, 2025, following a Board meeting on February 9, 2026. The results include both standalone and consolidated figures. Total consolidated revenue for the quarter stood at ₹44,776.17 lakhs, while consolidated profit after tax for the nine-month period reached ₹15,132.58 lakhs. The company noted that the impact of recent labor code consolidations was not material.
Board Approval and Results Overview
The Board of Directors of Neuland Laboratories Limited convened on February 9, 2026, to inter alia, approve the Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ending December 31, 2025. The meeting commenced at 2:45 p.m. and concluded at 3:45 p.m.
Consolidated Financial Highlights (Q3 FY2026)
The following table summarizes key consolidated figures (Amount in lakhs):
- Total Consolidated Income (Quarter Ended Dec 31, 2025): ₹44,776.17 lakhs (compared to ₹40,193.74 lakhs in Q3 FY2025).
- Total Consolidated Income (Nine Months Ended Dec 31, 2025): ₹1,26,444.31 lakhs (compared to ₹1,16,152.23 lakhs in the previous year period).
- Consolidated Profit After Tax (Quarter Ended Dec 31, 2025): ₹4,040.85 lakhs.
- Consolidated Profit After Tax (Nine Months Ended Dec 31, 2025): ₹15,132.58 lakhs (compared to ₹23,205.38 lakhs in the previous year period).
- Consolidated Earnings Per Share (Basic and Diluted, Nine Months): ₹117.95.
Standalone Financial Performance
The standalone results reflect the core operations of Neuland Laboratories Limited:
- Standalone Profit After Tax (Nine Months Ended Dec 31, 2025): ₹15,058.19 lakhs.
- Standalone Revenue from Operations (Quarter Ended Dec 31, 2025): ₹43,970.93 lakhs.
Segment Reporting (Consolidated Revenue)
The management considers the manufacture of active pharmaceutical ingredients and allied services as the single reportable operating segment. However, geographical revenue details were provided:
- Europe Segment Revenue (Nine Months Ended Dec 31, 2025): ₹37,883.13 lakhs.
- USA and North America Segment Revenue (Nine Months Ended Dec 31, 2025): ₹39,978.66 lakhs.
Auditor’s Review Conclusion
MSKA & Associates LLP issued a review report on the consolidated results. They confirmed that based on their review, nothing came to their attention that suggests the accompanying statement, prepared according to Ind AS 34, contained any material misstatement. The report noted that financial information for two subsidiaries, Neuland Laboratories K.K Japan and Neuland Laboratories Inc., USA, which constitute a minor portion of the total figures, were unaudited by their respective auditors but were considered not material to the Group.
Source: BSE
